# Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

> **NCT06905054** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 80 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis
- Liver Transplant, Complications
- PSC
- Biliary Strictures

## Interventions

- **DRUG:** Fenofibrate (drug)
- **DIAGNOSTIC_TEST:** Blood draw for the laboratory assessment
- **DIAGNOSTIC_TEST:** MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)

## Key facts

- **NCT ID:** NCT06905054
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905054, "Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06905054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*